UnitedHealth Group ($UNH) — Q2 2026 Earnings Preview
Earnings Date: July 16, 2026
As of: June 19, 2026
1. Key Metrics to Watch — Q2 2026 Consensus vs. Prior Quarters
| Metric | Q2 2026E (Consensus) | Q1 2026 (Actual) | Q2 2025 (Actual) | QoQ Change | YoY Change |
|---|---|---|---|---|---|
| Revenue ($M) | 110,945 | 109,652 | 111,585 | +1.2% | -0.6% |
| EPS (GAAP) | 4.54 | 6.28 | 4.22 | -27.7% | +7.6% |
| Medical Loss Ratio (MLR, %) | 83.9 | 84.8 | -90 bps | -90 bps | |
| EBITDA ($M) | 7,370 | 9,503 | 7,151 | -22.5% | +3.1% |
| Net Income ($M) | 4,376 | 6,084 | 4,271 | -28.0% | +2.5% |
Segment Estimates — Q2 2026 vs. Q1 2026
| Segment | Q2 2026E Commentary* | Q1 2026 Actual | Notes |
|---|---|---|---|
| UnitedHealthcare | Margin recovery focus, expect continued membership contraction, stable trends | See narrative | |
| Optum Health | Earnings to moderate from Q1, majority of FY earnings in H1 | $1.3B adj. earnings | Seasonality shift |
| Optum Insight | Back-half weighted earnings, AI product ramp | AI transition | |
| Optum Rx | Back-half weighted, onboarding new clients | Membership offset by UHC contraction |
* Segment-level consensus not available; see management commentary and guidance below.
2. Recent Guidance & Management Commentary — Near-Term Outlook
| Date | Metric/Theme | Guidance/Commentary | Source Document |
|---|---|---|---|
| Apr 21, 2026 | Full-Year 2026 EPS | Updated outlook to greater than $18.25 per share. | Q1 2026 ET |
| Apr 21, 2026 | Q2 2026 EPS cadence | "We continue to expect approximately 2/3 of earnings in the first half of the year and the remaining 1/3 in the second half." | Q1 2026 ET |
| Apr 21, 2026 | Segment earnings cadence | "UnitedHealthcare earnings are over 75% weighted to the first half...Optum Health...significant majority...in the first half. Optum Insight and Optum Rx...~60% of earnings in the second half." | Q1 2026 ET |
| Apr 21, 2026 | Medical Cost Ratio (MLR) | "First half levels more than 250 basis points below the midpoint of our full year guidance and second half levels more than 200 basis points above." | Q1 2026 ET |
| Apr 21, 2026 | Medicare Advantage Trend | "Trend is progressing in line with our expectation...pricing assumption of around 10% into 2026...modest favorability in government programs." | Q1 2026 ET |
| Apr 21, 2026 | Medicaid | "Continue to expect membership attrition and negative margins in 2026...modest margin improvements beginning in 2027." | Q1 2026 ET |
| Apr 21, 2026 | Commercial/ACA | "Membership levels, renewals and trends were generally in line...pricing actions...preserving margin while contributing to some moderation in growth." | Q1 2026 ET |
| Apr 21, 2026 | Optum Health | "Adjusted earnings of $1.3 billion reflect pricing and operational improvements...efforts are focused on management and process improvements that steadily improve margins at Optum Health for 2026 and accelerate into 2027." | Q1 2026 ET |
| Apr 21, 2026 | Optum Rx | "Onboarding more than 800 new clients...utilization and drug cost trends were as expected, with scripts down slightly year-over-year." | Q1 2026 ET |
| Apr 21, 2026 | Optum Insight | "New AI-first products continue to gain traction...earnings more naturally weighted to the back half." | Q1 2026 ET |
| Jan 27, 2026 | Full-Year 2026 Revenue | "We expect revenues of approximately $440 billion." | Q4 2025 ET |
| Jan 27, 2026 | Full-Year 2026 EPS | "Net earnings of at least $17.10 per share and adjusted net earnings of greater than $17.75 per share." | Q4 2025 ET |
| Jan 27, 2026 | MLR 2026 | "Expected to be 88.8%, plus or minus 50 basis points." | Q4 2025 ET |
| Jan 27, 2026 | Operating Cost Ratio 2026 | "Expected to be 12.8%, plus or minus 50 basis points." | Q4 2025 ET |
| Jan 27, 2026 | Optum Health Margin Target | "Long-term sustainable margin levels of 6% to 8%." | Q4 2025 ET |
| Jan 27, 2026 | Optum Health 2026 Earnings | "Expect operating earnings growth of approximately 9% while expanding margins by approximately 30 basis points." | Q4 2025 ET |
| Jan 27, 2026 | Optum Insight 2026 Earnings | "Expect earnings growth of greater than 4% while expanding margins by approximately 90 basis points." | Q4 2025 ET |
| Jan 27, 2026 | Optum Rx 2026 Earnings | "Expect operating earnings growth from expanding margins by approximately 20 basis points on an adjusted basis." | Q4 2025 ET |
3. What to Expect This Quarter
Revenue and EPS
- Consensus expects Q2 2026 revenue of $110.9B and GAAP EPS of $4.54.
- Management has guided to full-year adjusted EPS of greater than $18.25, with approximately two-thirds of earnings expected in the first half, implying a sequential step-down in Q2 EPS from Q1's $6.28.
Segment Performance
- UnitedHealthcare: Focus remains on margin recovery over membership growth, especially in Medicare and commercial. Membership contraction is expected to continue, particularly in ACA and Medicare Advantage, but pricing actions are supporting margin stability.
- Optum Health: Q1 saw strong adjusted earnings ($1.3B), but management expects earnings to moderate through the year due to seasonality and the shift of Optum Financial into Optum Insight. Operational improvements and value-based care execution are key themes.
- Optum Insight: Earnings are expected to be back-half weighted as legacy products are decommissioned and AI-first solutions ramp up.
- Optum Rx: Also back-half weighted, with 800+ new clients being onboarded. Drug cost trends and script volumes are in line with expectations, but membership contraction at UHC offsets some growth.
Medical Loss Ratio (MLR)
- Q1 2026 MLR was 83.9%, down 90 bps YoY. Management expects first-half MLR to be more than 250 bps below the full-year midpoint, with a rise in the second half.
4. Key Themes Investors Are Watching
- Margin Recovery and Cost Trends: Investors will focus on whether margin recovery in Medicare and commercial is tracking to plan, and if medical cost trends remain stable at elevated levels (~10% for Medicare Advantage).
- Membership Dynamics: Continued contraction in Medicare Advantage and ACA membership is expected; investors will watch for any signs of stabilization or further downside.
- AI and Productivity Initiatives: Management is investing ~$1.5B in AI in 2026, with early signs of productivity gains and digital engagement. The impact on SG&A and segment profitability will be closely watched.
- Optum Segment Execution: Progress in Optum Health's value-based care model, Optum Insight's AI transition, and Optum Rx's client onboarding and transparency initiatives are all under scrutiny.
- Regulatory and Policy Environment: Updates on Medicaid rate adequacy, Medicare Advantage funding, and PBM legislative changes (especially in Tennessee) are key external risks.
5. Catalysts and Risks Into the Print
Catalysts:
- Evidence of sustained margin improvement in UnitedHealthcare and Optum Health.
- Early returns from AI investments driving cost efficiencies or revenue opportunities.
- Positive updates on Optum Rx client onboarding and retention.
- Clarity on regulatory headwinds, especially in Medicaid and PBM.
Risks:
- Upside risk to medical cost trends, especially if utilization or acuity rises unexpectedly.
- Further downside in membership, particularly in Medicare Advantage or ACA.
- Delays or setbacks in Optum Insight's AI product ramp or Optum Health's operational turnaround.
- Adverse regulatory developments, especially in PBM or Medicaid funding.
6. Setup and Positioning Summary
- Stock Performance: Not provided in the source documents.
- Sentiment: Management commentary has been constructive, emphasizing operational progress, margin recovery, and AI-driven transformation. Buybacks have resumed earlier than planned, with at least $2B expected to be deployed by end of Q2, reflecting management's confidence in intrinsic value.
- Positioning Summary: The setup into Q2 2026 is one of cautious optimism: management has delivered a strong Q1, raised full-year EPS guidance, and is executing on margin and productivity initiatives. However, the market remains focused on the sustainability of these improvements amid ongoing membership contraction and elevated cost trends.
Sources:
All data and commentary are sourced from UnitedHealth Group's Q1 2026 and Q4 2025 earnings call transcripts and related filings between Jan 1, 2026 and 2026-07-15. No information outside this window or from other sources has been used.
